Top 20 Women Health Focusing Companies of 2024 Based on Market Cap

Share this

Top 20 Women Health Focusing Companies of 2024 Based on Market Cap


  • While the World celebrated International Women’s Day, PharmaShots was busy preparing an exciting report on the Top 20 Women Health Focusing Companies Based on Market Cap
  • Women's Health Market size was valued at $38.10B in 2023 and is expected to register $58.10B by 2030 with a CAGR of 4.9 percent. AbbVie managed to secure the first position with a market cap of $319.84B following the acquisition of Allergan, followed by Abbott Laboratories with $207.08B and Fuzi Pharma Co. Ltd with $281.9M respectively
  • To get a curated report of your liking, reach out to us at connect@pharmashots.com with the subject line Bespoke


Market Cap: $3.3K

Founded Year: 2003

Total Employees: N/A

Headquarters: British Columbia, Canada

Stock Exchange: OTCMKTS

  • Callitas Therapeutics is a biopharma company that develops and delivers products and technologies for the well-being of humans. The company primarily develops therapies dedicated to female health and wellness
  • Therapy areas focused on by the company are Obesity, Infertility, and Intimacy Issues. There are a wide range of products developed by the company targeting women’s health
  • ToConceive, a fertility-enhancing moisturizer, Orlistat, a US FDA-approved weight management drug that is sold by Roche by the brand name Xenical, and Extrinsa, developed to address the lack of female sexual dysfunction solutions 


Market Cap: $128K

Founded Year: 2007

Total Employees: ~40

Headquarters: California, United States

Stock Exchange: OTCMKTS

  • A commercial-stage biopharma company focused to develop and commercialize products attributed to serving the unmet needs of women’s health and reproductive health 
  • In May 2022, the company received the US FDA’s approval for Phexxi, a hormone-free, women-controlled prescription contraceptive gel for women
  • Moreover, the company is currently evaluating EVO100 under clinical trials for the prevention of Urogenital Chlamydia and Gonorrhea in women and EVO200 for the reduction of recurrent Bacterial Vaginosis (BV) 


Market Cap: $339K

Founded Year: 2012

Total Employees: ~50

Headquarters: Stockholm, Sweden

Stock Exchange: STO

  • Bonzun is a FemTech company that provides healthcare services to women, caregivers, and doctors globally. The company initiated its business to improve women’s health by launching its first service, virtual midwife, in 2014
  • Later in 2019, the company further launched its women-centric service called Bonzun IVF, a personalized IVF app developed to enhance the effectiveness of fertility treatments 
  • The company recently launched a new service called Bonzun Evolve, which is developed to strengthen self-leadership and coping mechanisms to deal with work-induced stress


Market Cap: $2.03M

Founded Year: 1997

Total Employees: ~20

Headquarters: New Jersey, United States

Stock Exchange: NASDAQ

  • Inspired by the idea of meeting the unmet health needs of women, Agile Therapeutics is committed to infusing innovation into several women’s health therapeutic areas
  • Twirla, the company’s asset is a once-weekly prescription combination hormonal contraceptive patch that adds up to most of the company’s revenue
  • The company had employed its proprietary transdermal patch technology called Skinfusion to develop Twirla. Moreover, Agile has recently joined forces with Nurx to expand the commercialization of Twirla


Market Cap: $2.89M

Founded Year: 2007

Total Employees: ~20

Headquarters: Florida, United States

Stock Exchange:

  • INVO Bioscience is a biopharma company dedicated to the development and expansion of Assisted Reproductive Technology (ART) 
  • The company’s lead assets are INVOcell, a medical device developed to allow fertilization and early embryo development in vivo within the woman’s body. INVOcell approved by the US FDA in 2016, received the CE mark in 2019 
  • As a strategic step towards expanding the commercialization of INVOcell, the company is focused on opening “INVO Centers” to offer INVOcell and IVC procedures by acquiring IVF clinics and through distribution across fertility clinics in the United States 


Market Cap: $4.59M

Founded Year: 1923

Total Employees: ~10,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

  • An American pharmaceutical company, Organon & Co. discovers and develops therapeutic products targeted toward women’s health. Earlier, in Mar 2020, Merck & Co. announced the spin-off of its women’s health company Organon & Co. 
  • The company has a series of therapy areas covered under its pipeline, Bacterial Vaginosis (BV), Breast Cancer, Contraception, Endometriosis, Fertility, Hysterectomy, Menopause, Osteoporosis, Polycystic Ovarian Syndrome (PCOD), and Postpartum Hemorrhage (PPH) 
  • Moreover, the company also provides biosimilars as a step to improve healthcare economics and to enhance treatment access to patients


Market Cap: $5.33M

Founded Year: 2008

Total Employees: ~170

Headquarters: California, United States

Stock Exchange: OTCMKTS

  • A commercial-stage MedTech company, Minerva Surgical develops, manufactures, and commercializes invasive solutions to meet the uterine healthcare needs of women
  • The company develops minimally invasive alternatives to hysterectomy and thereby to address the most common cause of Abnormal Uterine Bleeding (AUB) 
  • Minerva ES and Genesys HTA are among the company’s lead assets approved by the US FDA as an endometrial ablation device 


Market Cap: $6.58M

Founded Year: 1998

Total Employees: ~4

Headquarters: Arizona, United States

Stock Exchange: NASDAQ

  • A commercial-stage biotech company, Creative Medical discovers and delivers biological therapeutics in Immunotherapy, Endocrinology, Urology, Neurology, and Orthopedics 
  • The company has a series of programs under its portfolio viz. AlloStem, ImmCelz, ipscelz, StemSpine, OVaStem, and CaverStem
  • Dedicated towards women’s well-being is the company’s FemCelz, a disposable kit used by physicians to perform autologous procedures to treat female sexual dysfunction


Market Cap: $9.86M

Founded Year: 2012

Total Employees: ~20

Headquarters: Geneva, Switzerland

Stock Exchange: SWX

  • ObsEva is a clinical-stage biopharma company that develops and commercializes therapeutic entities for severe medical conditions associated with women’s reproductive health and pregnancy
  • The company is currently developing Nolasiban as an oral oxytocin receptor agonist to improve clinical pregnancy and live birth rates in women undergoing IVF 
  • The company in-licensed Nolasiban from Ares Trading in Aug 2013 and now retains the exclusive rights to commercialize Nolasiban globally (except in the People’s Republic of China where Yuyuan BioScience was granted the sub-license) 


Market Cap: $17.65M

Founded Year: 1985

Total Employees: ~7,000

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

  • A US-based MedTech company, Hologic develops, manufactures, and delivers diagnostic products, surgical products, and imaging systems focussed on women's health
  • Hologic operates primarily in four segments, viz. Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Hologic proprietary core technologies include Target Capture/Nucleic Acid Extraction Technology, Transcription-Mediated Amplification Technology, Hybridization Protection Assay, and Dual Kinetic Assay Technologies
  • Celero Vacuum-Assisted Breast Biopsy Device, BioZorb Bioabsorbable Marker, MyoSure Tissue Removal Suite, NovaSure Endometrial Ablation, Aptima Virology, Aptima HCV Quant Dx Assay are among the company’s lead assets


Market Cap: $20.25M

Founded Year: 1958

Total Employees: ~15,000

Headquarters: California, United States

Stock Exchange: NASDAQ

  • An indispensable arm of Cooper Companies, Cooper Surgical focuses on advancing fertility therapies and women’s health with its wide range of products and services pertaining to women's health
  • A significant amount of the company’s revenue comes from point of healthcare delivery, fertility products, and services used in fertility clinics
  • The company boasts a strong portfolio of over 600 products and services, including fertility products and services, medical devices, cryostorage, and contraception. Paragard, a hormone-free Intrauterine Device (IUD), is among the company’s lead assets


Market Cap: $29.23M

Founded Year: 1999

Total Employees: ~230

Headquarters: Liège, Belgium

Stock Exchange: EBR

  • Driven by the noble vision of transforming Women's lives through innovation, Mithra Pharmaceuticals works dedicatedly in contraception and menopause. The company has two portfolios; one comprising innovative based on Estetrol and the other one remains complex therapeutics
  • With a strengthened technological platform with its Mithra CDMO that offers services ranging from pharmaceutical development to manufacturing. The company’s lead asset from the Estetrol pipeline is Estelle, contraception, and from the complex therapeutics pipeline lead assets are Myring and Tibelia
  • In 2023, Mithra generated revenue of $44.37M as compared to $71.9M in 2022


Market Cap: $30.01M

Founded Year: 1986

Total Employees: ~30

Headquarters: New Jersey, United States

Stock Exchange: NYSE

  • Palatin is a biopharma company dedicated to delivering first-in-class treatment based on select molecules that showcase the power of the melanocortin system. The company discovers and develops new-age therapies to improve the lives of patients living with inflammatory and autoimmune conditions
  • The company’s lead asset is Vyleesi, a prescription drug used to treat hyperactive sexual desire disorder (HSDD) in women who have not gone through menopause. Approved by the FDA on Jun 21, 2019, Vyleesi is a registered trademark for bremelanotide injection
  • In fiscal year 2023, Vyleesi registered net sales of $4.9M compared to $1.2M in 2022


Market Cap: $39.02M

Founded Year: 1993

Total Employees: ~80

Headquarters: Texas, United States

Stock Exchange: NASDAQ

  • Focussed on transforming women’s gynecologic health with innovative diagnostic devices, Aspira Women’s Health's primary focus remains the eradication of ovarian cancer
  • Aspira’s lead assets are OvaWatch, a non-invasive blood test used in early risk assessment of ovarian cancer in women, and Ova1Plus, a combination device that uses Aspira’s FDA-approved Ova1 and Overa to detect the risk of ovarian malignancy
  • Aspira’s pipeline drugs are OvaWatch longitudinal monitoring designed to detect adnexal masses for ovarian cancer risk and EndoCheck, a non-invasive test to help identify endometriosis


Market Cap: $40.92M

Founded Year: 2004

Total Employees: ~30

Headquarters: Georgia, United States

Stock Exchange: NASDAQ

  • With a noble aim to developing new-age therapeutics in underserved areas to benefit women, Femasys Inc. is a biomedical company focused on transforming women’s healthcare with innovative solutions
  • Femasys' lead assets are FemVue, a device that instills a consistent alternating pattern of saline and air in a continuous stream, FemCath, a selective delivery catheter, and Femcerv, an endocervical tissue sampler.
  • The company has high hopes for its product candidates viz: FemaSeed, an artificial insemination solution, FemBloc a permanent birth control, and FemEMB, an endometrial tissue sampler


Market Cap: $51.75M

Founded Year: 2005

Total Employees: ~30

Headquarters: California, United States

Stock Exchange: NASDAQ

  • Driven by a noble mission to develop new-age therapies to enhance women's health, Dare Bio's accelerator has a diverse portfolio of potential candidates in contraception, sexual health, vaginal health, menopause, and fertility
  • The company's only approved product is Xaciato, a vaginal gel, approved to treat bacterial vaginosis infection in female patients > 12 yrs. In March 2022, Dare Bio entered into an exclusive global license agreement with Organon to commercialize Xaciato
  • Dare Bio’s Ovaprene an investigational hormone-free monthly intravaginal contraceptive is currently being evaluated in the P-III trial


Market Cap: $68.39M

Founded Year: 2014

Total Employees: ~60

Headquarters: Omer, Israel

Stock Exchange: TLV

  • Pulsenmore Ltd. dedicatedly develops self-scan ultrasound devices for screening and clinical diagnosis. The company aims to improve accessibility with continuous care by providing efficient solutions through its devices
  • Pulsenmore has clearance for commercial use in Brazil, the EU, the UK, Switzerland, Australia, and Israel. In the US, Pulsenmore can only be used for investigational purposes.
  • Pulsenmore is a self-scan device that can be connected to the patient’s smartphone, guided by a user-friendly app and a clinician dashboard


Market Cap: $281.9M

Founded Year: 1965

Total Employees: ~1,600

Headquarters: Tokyo, Japan

Stock Exchange: TYO

  • Fuji Pharma develops, manufactures, and markets pharmaceutical products, including injection agents, internal drugs, diagnostic products, and drugs for external use to improve women’s health across the globe
  • Ranging from medical care for women, in vitro diagnostics, medical care products, and curative medicine to information on pharmaceuticals and health, Fuji Pharma works in a select disease domain with its reinforced R&D
  • Moreover, the company expects to expand its business by forming alliances with companies under late-stage development targeting therapy areas including Gynecology and Obstetrics Hematological Cancer along with companies focusing on Contract Media for Diagnostic Medicines


Market Cap: $207.08B

Founded Year: 1888

Total Employees: ~3,700

Headquarters: Illinois, United States

Stock Exchange:

  • An American multinational company, Abbott Laboratories develops and commercializes medical devices and healthcare products 
  • The company functions under six business segments, including Women’s Health, Metabolics, Gastroenterology, Multi-Specialty, Central Nervous System, and Vaccines
  • Under its Women’s Health segment, Abbott offers tailored solutions addressing women-related health concerns through menarche, pregnancy, and menopause. The products sold under the company’s Women Health segment include Femoston Mini (post-menopausal symptoms), Solfe Extra Tablet (iron deficiency anemia), and Cetropro vial (IVF)


Market Cap: $319.84B

Founded Year: 2013

Total Employees: ~50,000

Headquarters: Illinois, United States

Stock Exchange: NYSE

  • Allergan, a subsidiary of AbbVie, is an American pharmaceutical company that discovers, develops, and manufactures therapeutic drugs and medical devices 
  • The company majorly focuses on Medical Aesthetics, Eye Care, Central Nervous System, and Gastroenterology
  • The acquisition of Allergan was completed by AbbVie in 2020. Allergan’s aesthetics portfolio includes facial injectables, plastics and regenerative medicine, body contouring and skincare products


  • Annual reports
  • SEC Filings
  • Press releases
  • Company websites

Market Cap Source: Google Finance (06th Feb, 2024)

Currency Conversion: X-Rates (06th Feb, 2024)


  • All market caps were marked on 06th Feb, 2024
  • The number of employees for Callitas Therapeutics was not disclosed

Related Posts: Top 20 Radiopharma Companies Based on Market Cap






Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions